Burden and Prevention of Adverse Cardiac Events in Patients with Concomitant Chronic Heart Failure and Coronary Artery Disease: A Literature Review

Cardiovascular Therapeutics

Volumn 34, Issue 3, 2016, Pages 152-160

  Lavoie, Louis ^a   Khoury, Hanane ^a   Welner, Sharon ^a   Briere, Jean Baptiste ^b  

^a LASER Analytica   (Canada)

^b BAYER PHARMA AG   (Germany)

Author keywords

Adverse cardiac events; Antithrombotics; Coronary artery disease; Heart failure

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CORONARY ARTERY DISEASE; DRUG COST; ECONOMIC ASPECT; ECONOMIC BURDEN; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART FAILURE; HEART PROTECTION; HOSPITALIZATION; HUMAN; INCIDENCE; MEDICAL LITERATURE; PREVALENCE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REVIEW; CHRONIC DISEASE; COMORBIDITY; COST BENEFIT ANALYSIS; ECONOMICS; MORTALITY; MYOCARDIAL INFARCTION; PROGNOSIS; RISK FACTOR; STROKE; TIME FACTOR;

ANTICOAGULANTS; CHRONIC DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG COSTS; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROGNOSIS; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84969754408     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12180     Document Type: Review

References (44)

1. Liu L, Eisen HJ. Epidemiology of heart failure and scope of the problem. Cardiol Clin 2014;32:1-8. vii.
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146.
3. International Diabetes Federation. IDF diabetes atlas, 6th edition. Brussels, Belgium. 2013. http://www.idf.org/diabetesatlas/download-book. (Accessed 6 Jan 2014).
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
5. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
6. Hicks KA, Hung HMJ, Mahaffey KW, Mehran R. Standardized definitions for end point events in cardiovascular trials. 2010. http://www.clinpage.com/images/uploads/endpoint-defs_11-16-2010.pdf. (Accessed 21 Jun 2013).
7. Abildstrom SZ, Ottesen MM, Rask-Madsen C, Andersen PK, Rosthoj S, Torp-Pedersen C, Kober L. Sudden cardiovascular death following myocardial infarction: the importance of left ventricular systolic dysfunction and congestive heart failure. Int J Cardiol 2005;104:184-189.
8. Bertomeu-Gonzalez V, Nunez J, Nunez E, et al. Prognostic effect of renal dysfunction after ST-segment elevation myocardial infarction with and without heart failure. Int J Cardiol 2006;112:159-165.
9. Bonde L, Sorensen R, Fosbol EL, et al. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: A nationwide study. J Am Coll Cardiol 2010;55:1300-1307.
10. Hung J, Teng TH, Finn J, et al. Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: A population-based study of 20, 812 patients with first acute myocardial infarction in Western Australia. J Am Heart Assoc 2013;2:1-9.
11. Juilliere Y, Cambou JP, Bataille V, et al. Heart failure in acute myocardial infarction: A comparison between patients with or without heart failure criteria from the FAST-MI registry. Rev Esp Cardiol (Engl Ed) 2012;65:326-333.
12. Lewinter C, Bland JM, Crouch S, et al. Impact of aspirin and statins on long-term survival in patients hospitalized with acute myocardial infarction complicated by heart failure: An analysis of 1706 patients. Eur J Heart Fail 2014;16:95-102.
13. Velazquez EJ, Francis GS, Armstrong PW, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: The VALIANT registry. Eur Heart J 2004;25:1911-1919.
14. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-1579.
15. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123-1133.
16. McMurray JJV, Stewart S. The burden of heart failure. Eur Heart J Suppl 2002;4(Suppl. D):D50-D58.
17. Gheorghiade M, Vaduganathan M, Fonarow GC, et al. Anticoagulation in heart failure: Current status and future direction. Heart Fail Rev 2013;18:797-813.
18. Lu KJ, Yan BP, Ajani AE, et al. Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: Analysis of the Melbourne Interventional Group registry. Eur J Heart Fail 2011;13:416-422.
19. Nagendran J, Norris CM, Appoo JJ, Ross DB, Nagendran J. Left ventricular end-diastolic pressure predicts survival in coronary artery bypass graft surgery patients. Ann Thorac Surg 2014;97:1343-1347.
20. Ouzounian M, Tu JV, Austin PC, Chong A, Liu PP, Lee DS. Statin therapy and clinical outcomes in heart failure: A propensity-matched analysis. J Card Fail 2009;15:241-248.
21. Rosolova H, Cech J, Simon J, et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic-a report from the EuroHeart Failure Survey. Eur J Heart Fail 2005;7:780-783.
22. Andersson C, Merie C, Jorgensen M, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: A Danish nationwide cohort study. JAMA Intern Med 2014;174:336-344.
23. Rusinaru D, Houpe D, Szymanski C, Levy F, Marechaux S, Tribouilloy C. Coronary artery disease and 10-year outcome after hospital admission for heart failure with preserved and with reduced ejection fraction. Eur J Heart Fail 2014;16:967-976.
24. Fumagalli S, Gasparini M, Landolina M, et al. Determinants of all-cause mortality in different age groups in patients with severe systolic left ventricular dysfunction receiving an implantable cardioverter defibrillator (from the Italian ClinicalService Multicenter Observational Project). Am J Cardiol 2014;113:1691-1696.
25. Marui A, Kimura T, Nishiwaki N, et al. Three-year outcomes after percutaneous coronary intervention and coronary artery bypass grafting in patients with heart failure: From the CREDO-Kyoto percutaneous coronary intervention/coronary artery bypass graft registry cohort-2. Eur J Cardiothorac Surg 2015;47:316-321.
26. Gheorghiade M, Flaherty JD, Fonarow GC, et al. Coronary artery disease, coronary revascularization, and outcomes in chronic advanced systolic heart failure. Int J Cardiol 2011;151:69-75.
27. Mentz RJ, Allen BD, Kwasny MJ, et al. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur J Heart Fail 2013;15:61-68.
28. Manzano L, Babalis D, Roughton M, et al. Predictors of clinical outcomes in elderly patients with heart failure. Eur J Heart Fail 2011;13:528-536.
29. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011;364:1607-1616.
30. Smilde TD, Hillege HL, Navis G, Boomsma F, de ZD, van Veldhuisen DJ. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: Association with neurohormonal activation and survival. Am Heart J 2004;148:165-172.
31. Patterson ME, Grant WC, Glickman SW, et al. Resource use and costs of treatment with anticoagulation and antiplatelet agents: Results of the WATCH trial economic evaluation. J Card Fail 2009;15:819-827.
32. McMurray JJ, Andersson FL, Stewart S, et al. Resource utilization and costs in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006;27:1447-1458.
33. Colombo GL, Caruggi M, Ottolini C, Maggioni AP. Candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vasc Health Risk Manag 2008;4:223-234.
34. Austin J, Williams WR, Hutchison S. Multidisciplinary management of elderly patients with chronic heart failure: Five year outcome measures in death and survivor groups. Eur J Cardiovasc Nurs 2009;8:34-39.
35. Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic heart failure and their carers: A 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail 2010;12:1002-1008.
36. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147-e239.
37. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012;126:e354-e471.
38. Krum H, Meehan A, Varigos J, Loane PR, Billah B. Does the presence of heart failure alter prescribing of drug therapy after myocardial infarction? A multicentre study. Med J Aust. 2006;185:191-194.
39. Ezekowitz J, McAlister FA, Humphries KH, Norris CM, Tonelli M, Ghali WA, Knudtson ML. The association among renal insufficiency, pharmacotherapy, and outcomes in 6427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004;44:1587-1592.
40. Newby LK, LaPointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006;113:203-212.
41. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK. Efficacy of antithrombotic therapy in chronic heart failure: The HELAS study. Eur J Heart Fail 2006;8:428-432.
42. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012;366:1859-1869.
43. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616-1624.
44. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.